High-quality segmentation is important for AI-driven radiological research and clinical practice, with the potential to play an even more prominent role in the future. As medical imaging advances, accurately segmenting anatomical and pathological structures is increasingly used to obtain quantitative data and valuable insights. Segmentation and volumetric analysis could enable more precise diagnosis, treatment planning, and patient monitoring. These guidelines aim to improve segmentation accuracy and consistency, allowing for better decision-making in both research and clinical environments. Practical advice on planning and organization is provided, focusing on quality, precision, and communication among clinical teams. Additionally, tips and strategies for improving segmentation practices in radiology and radiation oncology are discussed, as are potential pitfalls to avoid. KEY POINTS: As AI continues to advance, volumetry will become more integrated into clinical practice, making it essential for radiologists to stay informed about its applications in diagnosis and treatment planning. There is a significant lack of practical guidelines and resources tailored specifically for radiologists on technical topics like segmentation and volumetric analysis. Establishing clear rules and best practices for segmentation can streamline volumetric assessment in clinical settings, making it easier to manage and leading to more accurate decision-making for patient care.

This review explores the use of brain age estimation from MRI scans as a biomarker of brain health. With disorders like Alzheimer's and Parkinson's increasing globally, there is an urgent need for early detection tools that can identify at-risk individuals before cognitive symptoms emerge. Brain age offers a noninvasive, quantitative measure of neurobiological ageing, with applications in early diagnosis, disease monitoring, and personalized medicine. Studies show that individuals with Alzheimer's, mild cognitive impairment (MCI), and Parkinson's have older brain ages than their chronological age. Longitudinal research indicates that brain-predicted age difference (brain-PAD) rises with disease progression and often precedes cognitive decline. Advances in deep learning and multimodal imaging have improved the accuracy and interpretability of brain age predictions. Moreover, socioeconomic disparities and environmental factors significantly affect brain aging, highlighting the need for inclusive models. Brain age estimation is a promising biomarker for identify future risk of neurodegenerative disease, monitoring progression, and helping prognosis. Challenges like implementation of standardization, demographic biases, and interpretability remain. Future research should integrate brain age with biomarkers and multimodal imaging to enhance early diagnosis and intervention strategies.

Artificial intelligence (AI) is rapidly transforming radiology, with applications spanning disease detection, lesion segmentation, workflow optimization, and report generation. As these tools become more integrated into clinical practice, new concerns have emerged regarding their vulnerability to adversarial attacks. This review provides an in-depth overview of adversarial AI in radiology, a topic of growing relevance in both research and clinical domains. It begins by outlining the foundational concepts and model characteristics that make machine learning systems particularly susceptible to adversarial manipulation. A structured taxonomy of attack types is presented, including distinctions based on attacker knowledge, goals, timing, and computational frequency. The clinical implications of these attacks are then examined across key radiology tasks, with literature highlighting risks to disease classification, image segmentation and reconstruction, and report generation. Potential downstream consequences such as patient harm, operational disruption, and loss of trust are discussed. Current mitigation strategies are reviewed, spanning input-level defenses, model training modifications, and certified robustness approaches. In parallel, the role of broader lifecycle and safeguard strategies are considered. By consolidating current knowledge across technical and clinical domains, this review helps identify gaps, inform future research priorities, and guide the development of robust, trustworthy AI systems in radiology.

Desmoid tumors are rare, locally invasive soft-tissue tumors with unpredictable clinical behavior. Imaging plays a crucial role in their diagnosis, measurement of disease burden, and assessment of treatment response. However, desmoid tumors' unique imaging features present challenges to conventional imaging metrics. The heterogeneous nature of these tumors, with a variable composition (fibrous, myxoid, or cellular), complicates accurate delineation of tumor boundaries and volumetric assessment. Furthermore, desmoid tumors can demonstrate prolonged stability or spontaneous regression, and biologic quiescence is often manifested by collagenization rather than bulk size reduction, making traditional size-based response criteria, such as Response Evaluation Criteria in Solid Tumors (RECIST), suboptimal. To overcome these limitations, advanced imaging techniques offer promising opportunities. Functional and parametric imaging methods, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, and T2 relaxometry, can provide insights into tumor cellularity and maturation. Radiomics and artificial intelligence approaches may enhance quantitative analysis by extracting and correlating complex imaging features with biological behavior. Moreover, imaging biomarkers could facilitate earlier detection of treatment efficacy or resistance, enabling tailored therapy. By integrating advanced imaging into clinical practice, it may be possible to refine the evaluation of disease burden and treatment response, ultimately improving the management and outcomes of patients with desmoid tumors.

Neuroimaging screening and surveillance is one of the first frontline diagnostic tools leveraged in the acute assessment (first 24 h postinjury) of patients suspected to have traumatic brain injury (TBI). While imaging, in particular computed tomography, is used almost universally in emergency departments worldwide to evaluate possible features of TBI, there is no currently agreed-upon reporting system, standard terminology, or framework to contextualize brain imaging findings with other available medical, psychosocial, and environmental data. In 2023, the NIH-National Institute of Neurological Disorders and Stroke convened six working groups of international experts in TBI to develop a new framework for nomenclature and classification. The goal of this effort was to propose a more granular system of injury classification that incorporates recent progress in imaging biomarkers, blood-based biomarkers, and injury and recovery modifiers to replace the commonly used Glasgow Coma Scale-based diagnosis groups of mild, moderate, and severe TBI, which have shown relatively poor diagnostic, prognostic, and therapeutic utility. Motivated by prior efforts to standardize the nomenclature for pathoanatomic imaging findings of TBI for research and clinical trials, along with more recent studies supporting the refinement of the originally proposed definitions, the Imaging Working Group sought to update and expand this application specifically for consideration of use in clinical practice. Here we report the recommendations of this working group to enable the translation of structured imaging common data elements to the standard of care. These leverage recent advances in imaging technology, electronic medical record (EMR) systems, and artificial intelligence (AI), along with input from key stakeholders, including patients with lived experience, caretakers, providers across medical disciplines, radiology industry partners, and policymakers. It was recommended that (1) there would be updates to the definitions of key imaging features used for this system of classification and that these should be further refined as new evidence of the underlying pathology driving the signal change is identified; (2) there would be an efficient, integrated tool embedded in the EMR imaging reporting system developed in collaboration with industry partners; (3) this would include AI-generated evidence-based feature clusters with diagnostic, prognostic, and therapeutic implications; and (4) a "patient translator" would be developed in parallel to assist patients and families in understanding these imaging features. In addition, important disclaimers would be provided regarding known limitations of current technology until such time as they are overcome, such as resolution and sequence parameter considerations. The end goal is a multifaceted TBI characterization model incorporating clinical, imaging, blood biomarker, and psychosocial and environmental modifiers to better serve patients not only acutely but also through the postinjury continuum in the days, months, and years that follow TBI.

Neuropsychiatric disorders have complex pathological mechanism, pronounced clinical heterogeneity, and a prolonged preclinical phase, which presents a challenge for early diagnosis and development of precise intervention strategies. With the development of large-scale multimodal neuroimaging datasets and advancement of artificial intelligence (AI) algorithms, the integration of multimodal imaging with AI techniques has emerged as a pivotal avenue for early detection and tailoring individualized treatment for neuropsychiatric disorders. To support these advances, in this review, we outline multimodal neuroimaging techniques, AI methods, and strategies for multimodal data fusion. We highlight applications of multimodal AI based on neuroimaging data in precision medicine for neuropsychiatric disorders, discussing challenges in clinical adoption, their emerging solutions, and future directions.

Artificial intelligence (AI) has emerged as a transformative force in orthopedic surgery. Potentially encompassing pre-, intra-, and postoperative processes, it can process complex medical imaging, provide real-time surgical guidance, and analyze large datasets for outcome prediction and optimization. AI has shown improvements in surgical precision, efficiency, and patient outcomes across orthopedic subspecialties, and large language models and agentic AI systems are expanding AI utility beyond surgical applications into areas such as clinical documentation, patient education, and autonomous decision support. The successful implementation of AI in orthopedic surgery requires careful attention to validation, regulatory compliance, and healthcare system integration. As these technologies continue to advance, maintaining the balance between innovation and patient safety remains crucial, with the ultimate goal of achieving more personalized, efficient, and equitable healthcare delivery while preserving the essential role of human clinical judgment. This review examines the current landscape and future trajectory of AI applications in orthopedic surgery, highlighting both technological advances and their clinical impact. Studies have suggested that AI-assisted procedures achieve higher accuracy and better functional outcomes compared to conventional methods, while reducing operative times and complications. However, these technologies are designed to augment rather than replace clinical expertise, serving as sophisticated tools to enhance surgeons' capabilities and improve patient care.

Pancreatic Cancer (PC) is a highly aggressive tumor that is mainly diagnosed at later stages. Various imaging technologies, such as CT, MRI, and EUS, possess limitations in early PC diagnosis. Therefore, this review article explores the various innovative biomarkers for PC detection, such as DNA methylation, Noncoding RNAs, and proteomic biomarkers, and the role of AI in PC detection at early stages. Innovative biomarkers, such as DNA methylation genes, show higher specificity and sensitivity in PC diagnosis. Additionally, various non-coding RNAs, such as long non-coding RNAs (lncRNAs) and microRNAs, show high diagnostic accuracy and serve as diagnostic and prognostic biomarkers. Additionally, proteomic biomarkers retain higher diagnostic accuracy in different body fluids. Apart from this, the utilization of AI showed that AI surpassed the radiologist's diagnostic performance in PC detection. The combination of AI and advanced biomarkers can revolutionize early PC detection. However, large-scale, prospective studies are needed to validate its clinical utility. Further. standardization of biomarker panels and AI algorithms is a vital step toward their reliable applications in early PC detection, ultimately improving patient outcomes.

Sinonasal pathology can be complex and requires a systematic and meticulous approach. Artificial Intelligence (AI) has the potential to improve diagnostic accuracy and efficiency in sinonasal imaging, but its clinical applicability remains an area of ongoing research. This systematic review evaluates the methodologies and clinical relevance of AI in detecting sinonasal pathology through radiological imaging. Key search terms included "artificial intelligence," "deep learning," "machine learning," "neural network," and "paranasal sinuses,". Abstract and full-text screening was conducted using predefined inclusion and exclusion criteria. Data were extracted on study design, AI architectures used (e.g., Convolutional Neural Networks (CNN), Machine Learning classifiers), and clinical characteristics, such as imaging modality (e.g., Computed Tomography (CT), Magnetic Resonance Imaging (MRI)). A total of 53 studies were analyzed, with 85% retrospective, 68% single-center, and 92.5% using internal databases. CT was the most common imaging modality (60.4%), and chronic rhinosinusitis without nasal polyposis (CRSsNP) was the most studied condition (34.0%). Forty-one studies employed neural networks, with classification as the most frequent AI task (35.8%). Key performance metrics included Area Under the Curve (AUC), accuracy, sensitivity, specificity, precision, and F1-score. Quality assessment based on CONSORT-AI yielded a mean score of 16.0 ± 2. AI shows promise in improving sinonasal imaging interpretation. However, as existing research is predominantly retrospective and single-center, further studies are needed to evaluate AI's generalizability and applicability. More research is also required to explore AI's role in treatment planning and post-treatment prediction for clinical integration.

Machine learning (ML), a subset of artificial intelligence (AI), utilizes advanced algorithms to learn patterns from data, enabling accurate predictions and decision-making without explicit programming. In orthopedic surgery, ML is transforming clinical practice, particularly in shoulder arthroplasty and rotator cuff tears (RCTs) management. This review explores the fundamental paradigms of ML, including supervised, unsupervised, and reinforcement learning, alongside key algorithms such as XGBoost, neural networks, and generative adversarial networks. In shoulder arthroplasty, ML accurately predicts postoperative outcomes, complications, and implant selection, facilitating personalized surgical planning and cost optimization. Predictive models, including ensemble learning methods, achieve over 90% accuracy in forecasting complications, while neural networks enhance surgical precision through AI-assisted navigation. In RCTs treatment, ML enhances diagnostic accuracy using deep learning models on magnetic resonance imaging and ultrasound, achieving area under the curve values exceeding 0.90. ML models also predict tear reparability with 85% accuracy and postoperative functional outcomes, including range of motion and patient-reported outcomes. Despite remarkable advancements, challenges such as data variability, model interpretability, and integration into clinical workflows persist. Future directions involve federated learning for robust model generalization and explainable AI to enhance transparency. ML continues to revolutionize orthopedic care by providing data-driven, personalized treatment strategies and optimizing surgical outcomes.